Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bio-Thera Solutions Has China’s First Adalimumab Biosimilar

Qletli Is Only The Second Biosimilar Approved In China

Executive Summary

Bio-Thera Solutions has secured only the second biosimilar approval ever from China’s NMPA, and the country’s first biosimilar approval for a rival to Humira (adalimumab).

You may also be interested in...



Shanghai Henlius CEO Wants To Capitalize On First-Mover Status

In an exclusive interview with Generics Bulletin, Dr. Scott Liu, co-founder, and CEO of Chinese biosimilars and biologics specialist Shanghai Henlius Biotech, has set out his vision for the firm’s future in China and around the globe.

Bio-Thera Launches Adalimumab In China

Bio-Thera Solutions has launched its first product in China, with its Qletli adalimumab biosimilar representing the first Humira rival to be approved under the country’s biosimilars pathway and just the second biosimilar approved overall.

Sorrento’s Partner Mabpharm Files For Infliximab In China

Banking on the burgeoning biosimilars approvals in China, Sorrento’s partner Mabpharm has filed in China for an infliximab biosimilar. Sorrento plans to follow this up with a US filing for a ‘biobetter’ version via the BLA route in 2020.

Related Content

Topics

UsernamePublicRestriction

Register

GB149350

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel